ASH 2021 | Patient selection for BTK inhibitors
Constantine Tam
• 12 Dec 2021
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, describes the characteristics of patients who are suited for Bruton’s tyrosine kinase (BTK) inhibitors. BTK inhibitors have certain advantages over other targeted therapies such as BCL-2 inhibitors as they are easier to administer in elderly patients and result in fewer cases of tumor lysis syndrome. The CLL14 trial (NCT02242942) has additionally suggested BTK inhibitors are more effective in patients with chronic lymphocytic leukemia (CLL) who have certain mutations such as 17p deletions or IGHV mutations. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
